SMAD4 haploinsufficiency in small intestinal neuroendocrine tumors

Tobias Hofving1, Erik Elias2, Anna Rehammar3

  • 1Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Box 425, SE-405 30, Gothenburg, Sweden.

BMC Cancer
|January 29, 2021
PubMed
Abstract

Insights

Loss of chromosome 18q and the SMAD4 gene is common in small intestinal neuroendocrine tumors (SINETs), potentially affecting protein levels and metastasis. This genetic event may confer a growth advantage, driving tumor progression.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Small intestinal neuroendocrine tumors (SINETs) often metastasize early.
  • The molecular drivers of SINET progression are poorly understood.
  • SINETs exhibit low mutation rates but frequent copy number alterations (CNAs).

Purpose of the Study:

  • To investigate the role of CNAs in SINET development and progression.
  • To characterize the impact of SMAD4 and CDKN1B alterations in SINETs.

Main Methods:

  • Comparative genomic hybridization (CGH) arrays analyzed 131 SINETs.
  • Tissue microarrays (TMAs) with 846 SINETs assessed SMAD4 and CDKN1B protein expression via immunohistochemistry (IHC).
  • Fluorescent in-situ hybridization (FISH) correlated protein levels with chromosome number; a Smad4+/- mouse model was used.

Main Results:

  • Loss of chromosome 18q/SMAD4 occurred in 71% of SINETs; focal loss of chromosome 12/CDKN1B in 9.4%.
  • Hemizygous SMAD4 loss correlated with reduced protein levels but did not cause hyperplasia in mice.
  • Low SMAD4 protein expression was linked to increased metastatic disease.

Conclusions:

  • Hemizygous loss of chromosome 18q/SMAD4 is the most frequent genetic event in SINETs.
  • This loss may influence SMAD4 protein levels and metastasis, suggesting a role in tumor spread.
  • Loss of chromosome 18 might provide a selective evolutionary advantage in SINETs.